全文获取类型
收费全文 | 379篇 |
免费 | 45篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 18篇 |
妇产科学 | 6篇 |
基础医学 | 47篇 |
口腔科学 | 7篇 |
临床医学 | 43篇 |
内科学 | 117篇 |
皮肤病学 | 5篇 |
神经病学 | 44篇 |
特种医学 | 11篇 |
外科学 | 40篇 |
综合类 | 2篇 |
预防医学 | 23篇 |
眼科学 | 4篇 |
药学 | 43篇 |
肿瘤学 | 13篇 |
出版年
2023年 | 1篇 |
2022年 | 8篇 |
2021年 | 12篇 |
2020年 | 12篇 |
2019年 | 12篇 |
2018年 | 17篇 |
2017年 | 20篇 |
2016年 | 15篇 |
2015年 | 19篇 |
2014年 | 12篇 |
2013年 | 20篇 |
2012年 | 44篇 |
2011年 | 32篇 |
2010年 | 17篇 |
2009年 | 17篇 |
2008年 | 19篇 |
2007年 | 9篇 |
2006年 | 15篇 |
2005年 | 22篇 |
2004年 | 14篇 |
2003年 | 11篇 |
2002年 | 11篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 6篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 6篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1985年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有427条查询结果,搜索用时 15 毫秒
51.
52.
Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke,nested within a rural cohort in Uganda 下载免费PDF全文
53.
54.
Univ.Prof. Dr. Heinz Ludwig Dr. Rayko Evstatiev Univ.Prof. Dr. Gabriela Kornek Univ.Prof. Dr. Matti Aapro Univ.Prof. Dr. Thomas Bauernhofer Dr. Veronika Buxhofer-Ausch Univ.Prof. Dr. Michael Fridrik Univ.Prof. Dr. Dietmar Geissler Univ.Prof. Dr. Klaus Geissler Univ.Prof. Dr. Heinz Gisslinger Dr. Elisabeth Koller Dr. Gerhard Kopetzky Dr. Alois Lang Priv.Doz. Dr. Holger Rumpold Univ.Prof. Dr. Michael Steurer Dr. Houman Kamali Univ.Prof. Dr. Hartmut Link 《Wiener klinische Wochenschrift》2015,127(23-24):907-919
55.
Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections 下载免费PDF全文
Morteza Abkar Jafar Amani Abbas Sahebghadam Lotfi Gholamreza Nikbakht Brujeni Saeed Alamian Mehdi Kamali 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(8):667-675
Brucellosis is a world prevalent endemic illness that is transmitted from domestic animals to humans. Brucella spp. exploits urease for survival in the harsh conditions of stomach during the gastrointestinal infection. In this study, we examined the immune response and the protection elicited by using recombinant Brucella urease (rUrease) vaccination in BALB/c mice. The urease gene was cloned in pET28a and the resulting recombinant protein was employed as subunit vaccine. Recombinant protein was administered subcutaneously and intraperitoneally. Dosage reduction was observed with subcutaneous (SC) vaccination when compared with intraperitoneal (IP) vaccination. rUrease induced mixed Th1–Th2 immune responses with high titers of specific IgG1 and IgG2a. In lymphocyte proliferation assay, splenocytes from IP and SC‐vaccinated mice displayed a strong recall proliferative response with high amounts of IL‐4, IL‐12 and IFN‐γ production. Vaccinated mice were challenged with virulent Brucella melitensis, B. abortus and B. suis. The SC vaccination route exhibited a higher degree of protection than IP vaccination (p value ≤ 0.05). Altogether, our results indicated that rUrease could be a useful antigen candidate for the development of subunit vaccines against brucellosis. 相似文献
56.
The pharmacokinetics and metabolism of an intravenous dose (500 mg) of paracetamol were studied in a group of non-insulin dependent diabetic patients (n = 10) and in a group of healthy control subjects (n = 9). Paracetamol clearance, half-life and the partial clearance to paracetamol glucuronide were not significantly different, but the partial clearance to paracetamol sulphate was significantly reduced (62 +/- 18 vs 86 +/- 17 ml h-1 kg-1 (mean +/- s.d.)) and the renal clearance of paracetamol was significantly increased (56 +/- 20 vs 22 +/- 6 ml h-1 kg-1 (mean +/- s.d.)) in the non-insulin dependent diabetic patients, compared with the control group. 相似文献
57.
The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. 下载免费PDF全文
1. The effects of pirenzepine on gastric emptying, salivary flow and saliva paracetamol concentrations were investigated in healthy volunteers. 2. Pirenzepine significantly reduced the area under the saliva flow-time curves (7.29 +/- 3.30 g min-1 h without pirenzepine; 4.19 +/- 2.59 g min-1 h with pirenzepine, P less than 0.01). Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine). 3. Mean ratios of saliva:plasma paracetamol AUC (1.06 +/- 0.24 without pirenzepine; 1.84 +/- 0.48 with pirenzepine, P less than 0.001) and saliva:plasma paracetamol Cmax (1.7 +/- 1.0 without pirenzepine; 6.5 +/- 2.7 with pirenzepine, P less than 0.01) were significantly increased by pirenzepine pretreatment, but there was a poor correlation between the percentage change in the area under the saliva flow-time curve and the percentage change in saliva paracetamol AUC (r = 0.47, P = 0.21). 4. The findings suggest that a) pirenzepine is a more selective antagonist of the muscarinic receptors in salivary glands than those in gastric smooth muscle and b) caution is required when using saliva paracetamol concentrations to determine the pharmacokinetics of the drug in the presence of other agents which may influence salivary flow rate. 相似文献
58.
59.
Validity of the Iwate criteria for patients with hepatocellular carcinoma undergoing minimally invasive liver resection 下载免费PDF全文
60.